Koppert is investing €800,000 (USD$939,000) in Amoéba S.A., following the recently signed five-year exclusive global distribution agreement for Amoéba’s biofungicide solution.

Amoéba’s biofungicide solution is based on the lysate of the amoeba Willaertia magna C2c, and is designed to combat fungal diseases such as downy mildew and powdery mildew in crops like grapes and vegetables. The product introduces a novel mode of action and fills what the company says is a critical gap in the current biocontrol offering, particularly in Europe and the United States.

“Koppert’s support both commercially and now financially, validates the long-term value of our biocontrol technology,” says Jean-François Doucet, CEO of Amoéba.

The EU has already approved the active substance in Q2 2024, with full product registrations expected by early 2026.

Under the agreement, Koppert will distribute the product under its own brand across 18 European countries and the U.S., with expansion discussions for Brazil underway.

The €800,000 investment is part of a broader capital increase by Amoéba aimed at funding production scale-up, working capital, and regulatory development.

“This investment underlines our deep confidence in Amoéba’s innovative approach and the strong commercial potential of this biofungicide,” says Martin Koppert, chief business officer of Koppert. “We are committed to accelerating the adoption of biological solutions that help growers transition to more sustainable practices.”